AU2014342995C1 - Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells - Google Patents

Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells Download PDF

Info

Publication number
AU2014342995C1
AU2014342995C1 AU2014342995A AU2014342995A AU2014342995C1 AU 2014342995 C1 AU2014342995 C1 AU 2014342995C1 AU 2014342995 A AU2014342995 A AU 2014342995A AU 2014342995 A AU2014342995 A AU 2014342995A AU 2014342995 C1 AU2014342995 C1 AU 2014342995C1
Authority
AU
Australia
Prior art keywords
pct
cells
stage
cell
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014342995A
Other languages
English (en)
Other versions
AU2014342995B2 (en
AU2014342995A1 (en
Inventor
Marcia BLACKMOORE
Benjamin Fryer
Daina LANIAUSKAS
Kostadinka LILOVA
Shelley Nelson
Elizabeth ROSOCHA
Haiyun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/998,974 external-priority patent/US10377989B2/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2014342995A1 publication Critical patent/AU2014342995A1/en
Publication of AU2014342995B2 publication Critical patent/AU2014342995B2/en
Priority to AU2018208707A priority Critical patent/AU2018208707A1/en
Application granted granted Critical
Publication of AU2014342995C1 publication Critical patent/AU2014342995C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2014342995A 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells Ceased AU2014342995C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018208707A AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361962158P 2013-11-01 2013-11-01
US61/962,158 2013-11-01
US13/998,974 US10377989B2 (en) 2012-12-31 2013-12-30 Methods for suspension cultures of human pluripotent stem cells
US13/998,974 2013-12-30
PCT/US2014/038993 WO2015065524A2 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018208707A Division AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Publications (3)

Publication Number Publication Date
AU2014342995A1 AU2014342995A1 (en) 2016-05-05
AU2014342995B2 AU2014342995B2 (en) 2018-04-26
AU2014342995C1 true AU2014342995C1 (en) 2018-08-09

Family

ID=53004904

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014342995A Ceased AU2014342995C1 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
AU2014343007A Ceased AU2014343007C1 (en) 2013-11-01 2014-06-17 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
AU2018208707A Abandoned AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
AU2018208717A Abandoned AU2018208717A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2014343007A Ceased AU2014343007C1 (en) 2013-11-01 2014-06-17 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
AU2018208707A Abandoned AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
AU2018208717A Abandoned AU2018208717A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Country Status (12)

Country Link
EP (2) EP3063268A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016534731A (cg-RX-API-DMAC7.html)
KR (4) KR20180128529A (cg-RX-API-DMAC7.html)
CN (2) CN105793413A (cg-RX-API-DMAC7.html)
AU (4) AU2014342995C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016009393A8 (cg-RX-API-DMAC7.html)
CA (2) CA2928639A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016005657A (cg-RX-API-DMAC7.html)
PH (2) PH12016500783A1 (cg-RX-API-DMAC7.html)
RU (2) RU2689710C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201603045VA (cg-RX-API-DMAC7.html)
WO (2) WO2015065524A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005657A (es) * 2013-11-01 2017-01-05 Janssen Biotech Inc Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas.
RU2771328C2 (ru) * 2016-06-23 2022-04-29 Титон Биотек, Инк. Клетки, экспрессирующие рецептор паратиреоидного гормона 1, и их применение
WO2018089011A1 (en) 2016-11-10 2018-05-17 Viacyte, Inc Pdx1 pancreatic endoderm cells in cell delivery devices and methods thereof
JP7024978B2 (ja) 2016-11-16 2022-03-03 サイナータ セラピューティクス リミテッド 多能性幹細胞のアッセイ
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
WO2019018818A1 (en) * 2017-07-21 2019-01-24 Semma Therapeutics, Inc. REAGGREGATION OF BETA PANCREATIC CELLS DERIVED FROM STEM CELLS
JP7000896B2 (ja) * 2017-08-23 2022-01-19 王子ホールディングス株式会社 細胞シート形成部材、細胞シート形成部材の製造方法、および、細胞シートの製造方法
EP3735457A4 (en) * 2018-01-05 2021-08-25 Platelet Biogenesis, Inc. COMPOSITIONS AND METHOD OF MANUFACTURING MEGAKARYOCYTE
WO2019143292A1 (en) 2018-01-18 2019-07-25 Agency For Science, Technology And Research Method for differentiation of human pluripotent stem cell lines in suspension culture
KR102115360B1 (ko) * 2018-05-30 2020-05-26 주식회사 바이블리오테카 성체 줄기세포 배양액 및 그 제조방법
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
US20220233298A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
CN114401752B (zh) 2019-05-31 2023-04-04 W.L.戈尔及同仁股份有限公司 具有受控氧扩散距离的细胞封装装置
WO2020243663A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
AU2020283056B2 (en) 2019-05-31 2023-06-08 Viacyte, Inc. A biocompatible membrane composite
WO2021041555A1 (en) * 2019-08-27 2021-03-04 United Therapeutics Corporation Methods and compositions for culturing alveolar cells
KR20220052370A (ko) 2019-09-05 2022-04-27 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11116798B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
CN114729323B (zh) * 2019-11-22 2024-09-17 诺和诺德股份有限公司 旋转聚集的神经微球及其应用
AU2021414617A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells
JPWO2022203051A1 (cg-RX-API-DMAC7.html) * 2021-03-25 2022-09-29
CN116218766A (zh) * 2023-04-21 2023-06-06 北京意胜生物科技有限公司 一种制备胰腺前体细胞的方法、培养基及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213805A (pt) * 2001-11-09 2005-08-16 Artecel Sciences Inc Células estromais derivadas de tecido adiposo para diferenciação endócrina do pâncreas e usos das mesmas
EP2733203B1 (en) * 2006-08-02 2018-10-10 Technion Research & Development Foundation Ltd. Methods of expanding embryonic stem cells in a suspension culture
EP2088190A4 (en) * 2006-11-09 2011-01-05 Japan Government METHOD FOR THE CULTURE AND PASSING OF AN EMBRYONAL PRIMATIVE STEM CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF THE EMBRYONAL STEM CELL
WO2008148105A1 (en) * 2007-05-25 2008-12-04 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
JP2010532172A (ja) * 2007-07-01 2010-10-07 ライフスキャン・インコーポレイテッド 単細胞の分化万能性幹細胞の培養
EP2271747B1 (en) * 2008-03-17 2016-09-07 Agency for Science, Technology And Research Microcarriers for pluripotent stem cell culture
KR20180018839A (ko) * 2008-06-30 2018-02-21 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
US8008075B2 (en) * 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
JP5761816B2 (ja) * 2009-08-12 2015-08-12 国立大学法人京都大学 多能性幹細胞から神経前駆細胞への分化誘導法
US8932857B2 (en) * 2010-06-15 2015-01-13 Kyoto University Method for selecting reduced differentiation resistance human induced pluripotent stem cells
ES2659393T3 (es) * 2010-08-31 2018-03-15 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
WO2012117333A1 (en) * 2011-02-28 2012-09-07 Stempeutics Research Malaysia Sdn Bhd Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof
US8951798B2 (en) * 2011-10-13 2015-02-10 Wisconsin Alumni Research Foundation Generation of cardiomyocytes from human pluripotent stem cells
SG11201403473QA (en) * 2011-12-22 2014-10-30 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10519422B2 (en) * 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
CA2896750A1 (en) * 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
MX2016005657A (es) * 2013-11-01 2017-01-05 Janssen Biotech Inc Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas.

Also Published As

Publication number Publication date
WO2015065524A2 (en) 2015-05-07
AU2014343007B2 (en) 2018-04-26
EP3063268A4 (en) 2017-11-29
MX2016005657A (es) 2017-01-05
AU2018208707A1 (en) 2018-08-16
SG11201603047PA (en) 2016-05-30
WO2015065524A3 (en) 2015-08-13
RU2016121409A (ru) 2017-12-04
KR20160079072A (ko) 2016-07-05
CN105683362A (zh) 2016-06-15
AU2018208717A1 (en) 2018-08-16
PH12016500783A1 (en) 2016-06-13
KR20160079071A (ko) 2016-07-05
EP3063268A2 (en) 2016-09-07
CN105793413A (zh) 2016-07-20
KR20180130001A (ko) 2018-12-05
MX2016005658A (es) 2017-01-05
CA2928741A1 (en) 2015-05-07
RU2016121404A3 (cg-RX-API-DMAC7.html) 2018-03-29
PH12016500782A1 (en) 2016-06-13
KR20180128529A (ko) 2018-12-03
RU2016121404A (ru) 2017-12-04
AU2014342995B2 (en) 2018-04-26
JP2016534731A (ja) 2016-11-10
AU2014343007A1 (en) 2016-05-05
BR112016009393A8 (pt) 2020-03-24
AU2014342995A1 (en) 2016-05-05
EP3063269A4 (en) 2017-07-12
WO2015065537A1 (en) 2015-05-07
SG11201603045VA (en) 2016-05-30
AU2014343007C1 (en) 2018-08-09
RU2689710C2 (ru) 2019-05-29
CA2928639A1 (en) 2015-05-07
RU2016121409A3 (cg-RX-API-DMAC7.html) 2018-03-29
JP2017500013A (ja) 2017-01-05
EP3063269A1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
AU2014342995C1 (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
US10377989B2 (en) Methods for suspension cultures of human pluripotent stem cells
JP6800854B2 (ja) 多能性幹細胞の懸濁培養
US10370644B2 (en) Method for making human pluripotent suspension cultures and cells derived therefrom

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAY 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAY 2018

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired